QNRX
Quoin Pharmaceuticals, Ltd.
$4.20
-10.64%
$8.4M
No data for this timeframe.
Vol
Market Cap$8.4M
Cap SizeNano Cap
Analyst ConsensusStrong Buy (89%)
Inst. Holders7 funds
Inst. Value$1.2M
Inst. Activity2 buys / 0 sells
SEC Reports5
Press Releases2
Recent Activity
Jun 4, 2026
SEC
LUCID CAPITAL MARKETS initiates QNRX at Buy — PT $30 (+558%)
ANALYST-UPGRADE — Impact 2/10
Jun 4, 2026
other
Quoin Pharmaceuticals Announces Japan's MHLW Grants Orphan Drug Designation for QRX003 in Netherton Syndrome
<p align="center"><em>-Designation provides regulatory and development incentives in Japan, includin
May 7, 2026
SEC
Quoin Pharmaceuticals reported Q1 2026 loss per ADS of $(1.77), beating consensus of $(2.26), with no revenue. The compa
PRESS-RELEASE — Impact 6/10
May 5, 2026
SEC
Lucid Capital Markets initiates QNRX at Buy with $30 PT — stock at $6.36, implying +372% upside
ANALYST-UPGRADE — Impact 2/10
Mar 19, 2026
Press
Quoin Pharmaceuticals announced it will release its Q4 and full-year 2025 financial results and provide a corporate upda
Impact 3/10
Mar 11, 2026
Press
Quoin Pharmaceuticals announced that the FDA has granted Fast Track Designation for QRX003 lotion (4%) for the treatment
Impact 7/10
Feb 4, 2026
Insider
Carter Denise P. was granted 318,750 shares
Chief Operating Officer
Feb 4, 2026
Insider
Leong Natalie Ee Mun was granted 12,211 shares
Director
Price Targets
$29.75
+608.3% upside
Strong Buy
Current $4.20
Low $14.00
Median $32.50
High $40.00
4 analysts
$14.00
$40.00
Analyst Ratings
2Strong Buy
6Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 4, 2026 | LUCID CAPITAL MARKETS | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-1.77 ▲ +18.4% | $-1.93 — $-1.61 | 72% YoY | 2 |
| Next Q | $-1.69 ▼ -62.0% | $-2.05 — $-1.32 | 75% YoY | 2 |
| Current FY | $-6.88 ▼ -24.0% | $-7.91 — $-5.85 | 2 | |
| Next FY | $-2.91 ▲ +7.6% | $-3.90 — $-1.92 | 58% YoY | 2 |
Latest Reports
BULLISH
ANALYST-UPGRADE
2/10
LUCID CAPITAL MARKETS initiates QNRX at Buy — PT $30 (+558%)
Jun 4, 2026
BULLISH
ANALYST-UPGRADE
2/10
Lucid Capital Markets initiates QNRX at Buy with $30 PT — stock at $6.36, implying +372% upside
May 5, 2026
NEUTRAL
Press
3/10
Quoin Pharmaceuticals announced it will release its Q4 and full-year 2025 financial results and provide a corporate upda
Mar 19, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| ROYAL BANK OF CANADA | — | — |
| Woodline Partners LP | $525.2K | — |
| Centiva Capital, LP | $396.0K | DOUBLED |
| CITADEL ADVISORS LLC | $214.6K | — |
| MORGAN STANLEY | $26.4K | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Feb 4, 2026 | Carter Denise | A | $0.00 |
| Feb 4, 2026 | Leong Natalie | A | $0.00 |
| Feb 4, 2026 | Myers Michael | A | $0.00 |
| Feb 4, 2026 | LANGER DENNIS | A | $0.00 |
| Feb 4, 2026 | Lawlor Sally | A | $0.00 |
7 institutional holders with $1.2M total value (178,933 shares) as of 2026-Q1. Top holders: ROYAL, Woodline, Centiva. Net buying activity: 2 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | ROYAL BANK OF CANADA | 11 | $0.00 | 0.0% | — |
| 2 | Woodline Partners LP | 79,582 | $525.2K | 44.5% | — |
| 3 | Centiva Capital, LP | 60,000 | $396.0K | 33.5% | DOUBLED +397.8% |
| 4 | CITADEL ADVISORS LLC | 32,519 | $214.6K | 18.2% | — |
| 5 | MORGAN STANLEY | 4,000 | $26.4K | 2.2% | ADD +33.3% |
| 6 | RHUMBLINE ADVISERS | 1,521 | $10.0K | 0.8% | ADD +37.7% |
| 7 | BARCLAYS PLC | 1,300 | $8.6K | 0.7% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| Centiva Capital, LP | DOUBLED | 12,053 | 60,000 | +397.8% | $396.0K | 2026-Q1 |
| MORGAN STANLEY | ADD | 3,000 | 4,000 | +33.3% | $26.4K | 2026-Q1 |
| RHUMBLINE ADVISERS | ADD | 1,210 | 1,666 | +37.7% | $24.0K | 2025-Q4 |
| UBS Group AG | NEAR_EXIT | 130 | 1 | -99.2% | $7.00 | 2025-Q3 |
8 unique insiders with 8 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Feb 4, 2026 | Carter Denise P. | Chief Operating Officer | AWARD | 318,750 | — | — |
| Feb 4, 2026 | Leong Natalie Ee Mun | Director | AWARD | 12,211 | — | — |
| Feb 4, 2026 | Myers Michael | Chief Executive Officer | AWARD | 318,750 | — | — |
| Feb 4, 2026 | LANGER DENNIS | Director | AWARD | 21,709 | — | — |
| Feb 4, 2026 | Lawlor Sally Bridget | Chief Financial Officer | AWARD | 85,250 | — | — |
| Feb 4, 2026 | SEMBER MICHAEL T | Director | AWARD | 8,141 | — | — |
| Feb 4, 2026 | Culverwell Anthony James | Director | AWARD | 21,709 | — | — |
| Feb 4, 2026 | Cooper Joseph Patrick | Director | AWARD | 8,141 | — | — |
5 SEC filing reports analyzed. Sentiment: 3 bullish, 0 bearish, 0 mixed, 2 neutral. Avg impact: 3.0/10.
BULLISH
ANALYST-UPGRADE
2/10
Lucid Capital Markets initiates QNRX at Buy with $30 PT — stock at $6.36, implying +372% upside
May 5, 2026
BULLISH
ANALYST-UPGRADE
2/10
LUCID CAPITAL MARKETS initiates QNRX at Buy — PT $30 (+558%)
Jun 4, 2026
BULLISH
PRESS-RELEASE
6/10
Quoin Pharmaceuticals reported Q1 2026 loss per ADS of $(1.77), beating consensus of $(2.26), with n
May 7, 2026
NEUTRAL
PRESS-RELEASE
2/10
Quoin Pharmaceuticals announced it will release Q1 2026 financial results and a corporate update on
Apr 30, 2026
NEUTRAL
8-K
3/10
Analysis based on filing metadata only — document content was unavailable. The 8-K filing for Quoin
Mar 11, 2026
Current analyst consensus: Strong Buy (89% buy). Based on 9 analysts: 2 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$29.75 mean target
+608.3% upside
Strong Buy (1.33)
$14.00 Low
$40.00 High
| Metric | Value |
|---|---|
| Current Price | $4.20 |
| Target Low | $14.00 |
| Target Mean | $29.75 |
| Target Median | $32.50 |
| Target High | $40.00 |
| # Analysts | 4 |
| Recommendation | Strong Buy (1.33) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-1.77 | $-1.93 | $-1.61 | 71.8% | +18.4% | — | $0.0B | 0.0% | 2 |
| Next Q 2026-09-30 |
$-1.69 | $-2.05 | $-1.32 | 74.8% | -62.0% | — | $0.0B | 0.0% | 2 |
| Current FY 2026-12-31 |
$-6.88 | $-7.91 | $-5.85 | — | -24.0% | 1↑ 0↓ | $0.0B | 0.0% | 2 |
| Next FY 2027-12-31 |
$-2.91 | $-3.90 | $-1.92 | 57.7% | +7.6% | — | $0.0B | 0.0% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-1.770 | |
| 7d ago | $-1.610 | -0.160 |
| 30d ago | $-2.170 | +0.400 |
| 60d ago | $-2.170 | +0.400 |
| 90d ago | $0.000 | -1.770 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 4, 2026 | LUCID CAPITAL MARKETS | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| May 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Apr 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Mar 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Feb 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Jan 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 4, 2026
other
Quoin Pharmaceuticals Announces Japan's MHLW Grants Orphan Drug Designation for QRX003 in Netherton Syndrome
<p align="center"><em>-Designation provides regulatory and development incentives in Japan, including up to 10 years of market exclusivity upon approv
May 7, 2026
earnings
Quoin Pharmaceuticals Provides Corporate Update and Reports First Quarter 2026 Financial Results
<p><em>– Filed Breakthrough Medicine Designation Application with Saudi FDA for QRX003 in Netherton Syndrome</em></p>
May 7, 2026
earnings_calendar
QNRX Q1 2026 Earnings Scheduled — 2026-05-07
Apr 30, 2026
earnings
Quoin Pharmaceuticals to Announce Corporate Update and First Quarter 2026 Financial Results on Thursday, May 7, 2026
<p>ASHBURN, Va., April 30, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage spec
Apr 28, 2026
fda
CORRECTION -- Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs
<p align="center"><em>Company Planning Multi-Pronged Approach for QRX009 Including Several Investigator </em><em>Led Clinical Studies in Key Indicatio
Mar 26, 2026
earnings
Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results
<p align="center"><em>– Closes Private Placement Financing of Up to $104.5 Million </em></p>
Mar 26, 2026
short_interest
FTD: QNRX — 75,835 shares ($0.7M) failed to deliver
Settlement: 20260326, Price: $9.27, FTD Value: $702,990.45, QUOIN PHARMACEUTICALS LTD SPON
Mar 25, 2026
other
Quoin Pharmaceuticals Provides Clinical and Regulatory Update from Constructive Type C Meeting with U.S. FDA for QRX003 in Netherton Syndrome
<p align="center"><em>FDA indicated that a single Phase 3 study may be sufficient to support marketing approval in the U.S.</em></p>
Mar 25, 2026
short_volume
Short Volume: QNRX — 56.7% short (0.4M / 0.8M)
Short: 434,697 | Exempt: 2,009 | TRF Vol: 766,978 | Short Ratio: 56.7% | Off-exchange volume (dark pool + OTC)
Mar 19, 2026
earnings
Quoin Pharmaceuticals to Announce Corporate Update and Fourth Quarter and Full-Year 2025 Financial Results on Thursday, March 26, 2026
<p>ASHBURN, Va., March 19, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage spec
Mar 11, 2026
fda
Quoin Pharmaceuticals Announces FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton Syndrome
<p><em>— Fast Track Designation facilitates development and expedites regulatory review of therapies addressing serious conditions with significant un
Mar 11, 2026
earnings_calendar
QNRX Q4 2025 Earnings After Market Close — 2026-03-11